@article{010afe397cf34ed59cba6833171171ef,
title = "Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2",
abstract = "Two doses of the BNT162b2 mRNA vaccine are highly effective against SARS-CoV-2. Here, we tested the antibody neutralization against Omicron SARS-CoV-2 after 2 and 3 doses of BNT162b2. Serum from vaccinated individuals was serially tested for its ability to neutralize wild-type SARS-CoV-2 (USA-WA1/2020) and an engineered USA-WA1/2020 bearing the Omicron spike glycoprotein. At 2 or 4 weeks post dose 2, the neutralization geometric mean titers (GMTs) against the wild-type and Omicron-spike viruses were 511 and 20, respectively; at 1 month post dose 3, the neutralization GMTs increased to 1,342 and 336; and at 4 months post dose 3, the neutralization GMTs decreased to 820 and 171. The data support a 3-dose vaccination strategy and provide a glimpse into the durability of the neutralization response against Omicron.",
keywords = "BNT162b2 vaccine, Pfizer vacine, SARS-CoV-2, neutralization, neutralization durability, variants",
author = "Hongjie Xia and Jing Zou and Chaitanya Kurhade and Hui Cai and Qi Yang and Mark Cutler and David Cooper and Alexander Muik and Jansen, {Kathrin U.} and Xuping Xie and Swanson, {Kena A.} and Shi, {Pei Yong}",
note = "Funding Information: We thank the Pfizer-BioNTech clinical trial C4591001 and NCT04368728 participants from whom the post-immunization human sera were obtained. We thank the many colleagues at Pfizer and BioNTech who developed and produced the BNT162b2 vaccine. We thank John Yun-Chung Chen and Cody Bills from the University of Texas Medical Branch at Galveston for help with plaque assays. A.M. K.U.J. X.X. K.A.S. and P.-Y.S. conceived the study. H.X. J.Z. C.K. H.C. Q.Y. M.C. D.C. X.X. and K.A.S. performed the experiments. H.X. J.Z. M.C. D.C. A.M. K.U.J. X.X. K.A.S. and P.-Y.S. analyzed the results. H.X. J.Z. X.X. K.A.S. and P.-Y.S. wrote the manuscript. M.C. D.C. K.U.J. X.X. K.A.S. and P.-Y.S. supervised the project. X.X. and P.-Y.S. have filed a patent on the reverse genetic system of SARS-CoV-2. H.X. J.Z. C.K. X.X. and P.-Y.S. received compensation from Pfizer to perform the project. H.C. Q.Y. M.C. D.C. K.U.J. and K.A.S. are employees of Pfizer and may hold stock options. A.M. is an employee of BioNTech and may hold stock options. Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",
year = "2022",
month = apr,
day = "13",
doi = "10.1016/j.chom.2022.02.015",
language = "English (US)",
volume = "30",
pages = "485--488.e3",
journal = "Cell Host and Microbe",
issn = "1931-3128",
publisher = "Cell Press",
number = "4",
}